Alpha technology
3 January 2018 | By PerkinElmer
Alpha (Amplified Luminescence Proximity Homogeneous Assay) bead-based technology for no-wash assays.
List view / Grid view
3 January 2018 | By PerkinElmer
Alpha (Amplified Luminescence Proximity Homogeneous Assay) bead-based technology for no-wash assays.
In this application note, PerkinElmer demonstrates the ease and utility of using AlphaLISA®, a homogeneous assay format, to screen for small molecular inhibitors of BET bromodomains.
Quickly gain new insights into chemical and biomolecular research data. Featuring guided search and analysis workflows and dynamic data visualisations.
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
2 January 2018 | By Charles River Laboratories
The webinar speakers highlight the collaboration between patient groups, charities, and academia led to the development of inhibitors targeting gliomas.
Better subtyping of diffuse large B-cell lymphomas can enhance diagnosis and guide treatment...
Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.
An international team of researchers have developed 3D cell cultures in which genes can be specifically modified to improve the use of targeted anti-cancer drugs...
Mitochondrial DNA (mtDNA) mutations cause severe disorders that are untreatable and mostly affect the nervous system. The difficulty in funding therapies may also be explained by the lack of viable modelling systems...
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
In this paper, Thermo Fisher Scientific aim to assess the performance of Thermo Scientific Varioskan LUX when running NanoBRET.
DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.
Progressing actives from a high-throughput screen (HTS) of a target protein into suitable starting points for lead identification is fraught with pitfalls. The volume and quality of the HTS output is a function of the quality of the screening library, as well as specific properties of both the target and…
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.